Literature DB >> 8852983

Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain.

I Raad1, R Hachem, N Leeds, R Sawaya, Z Salem, S Atweh.   

Abstract

We describe a patient with acute lymphocytic leukemia and multidrug-resistant tuberculosis of the brain and spinal cord. Despite treatment with six antituberculous drugs and a steroid medication for 11 months, there was no appreciable clinical or radiological improvement in the patient's condition. Within 5 months of initiating adjunctive therapy with IFN-gamma and granulocyte colony stimulating factors, substantial neurological and radiological improvement was noted. Therapy with IFN-gamma was continued for 12 months, resulting in complete resolution of the lesions in the brain and spinal cord.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852983     DOI: 10.1093/clinids/22.3.572

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  CpG oligodeoxynucleotides enhance host defense during murine tuberculosis.

Authors:  Nicole P Juffermans; Jaklien C Leemans; Sandrine Florquin; Annelies Verbon; Arend H Kolk; Peter Speelman; Sander J H van Deventer; Tom van der Poll
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Chemokine secretion by human polymorphonuclear granulocytes after stimulation with Mycobacterium tuberculosis and lipoarabinomannan.

Authors:  D D Riedel; S H Kaufmann
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

3.  Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.

Authors:  R Reljic; S O Clark; A Williams; G Falero-Diaz; M Singh; S Challacombe; P D Marsh; J Ivanyi
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

Review 4.  Th1/Th2 balance in infection.

Authors:  C Infante-Duarte; T Kamradt
Journal:  Springer Semin Immunopathol       Date:  1999

5.  Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent.

Authors:  Philippa Hillyer; Viraj P Mane; Lynnsie M Schramm; Montserrat Puig; Daniela Verthelyi; Aaron Chen; Zeng Zhao; Maria B Navarro; Kevin D Kirschman; Srikant Bykadi; Ronald G Jubin; Ronald L Rabin
Journal:  Immunol Cell Biol       Date:  2012-01-17       Impact factor: 5.126

6.  Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.

Authors:  Roberto Suárez-Méndez; Idrian García-García; Norma Fernández-Olivera; Magalys Valdés-Quintana; María T Milanés-Virelles; Dalia Carbonell; Delfina Machado-Molina; Carmen M Valenzuela-Silva; Pedro A López-Saura
Journal:  BMC Infect Dis       Date:  2004-10-22       Impact factor: 3.090

Review 7.  Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.

Authors:  Kai Ling Chin; Fadhilah Zulkipli Anis; Maria E Sarmiento; Mohd Nor Norazmi; Armando Acosta
Journal:  J Immunol Res       Date:  2017-06-20       Impact factor: 4.818

Review 8.  Therapeutic potential of interferon-gamma in tuberculosis.

Authors:  Svetlana A Berns; Julia A Isakova; Polina I Pekhtereva
Journal:  ADMET DMPK       Date:  2022-02-14

9.  Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis.

Authors:  Won-Jung Koh; O Jung Kwon; Gee Young Suh; Man Pyo Chung; Hojoong Kim; Nam Yong Lee; Tae Sung Kim; Kyung Soo Lee
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

10.  Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study.

Authors:  María T Milanés-Virelles; Idrian García-García; Yamilet Santos-Herrera; Magalys Valdés-Quintana; Carmen M Valenzuela-Silva; Gaspar Jiménez-Madrigal; Thelvia I Ramos-Gómez; Iraldo Bello-Rivero; Norma Fernández-Olivera; Reinaldo B Sánchez-de la Osa; Carmen Rodríguez-Acosta; Lidia González-Méndez; Gregorio Martínez-Sánchez; Pedro A López-Saura
Journal:  BMC Infect Dis       Date:  2008-02-11       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.